[Department of Error] Department of Error

Mora P, Aroda VR, Asong M, et al. Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial. Lancet 2026; 408: 607–20—In this Article, the second sentence of the ninth paragraph of the Discussion should read “The zenagamtide 25 mg and 50 mg groups spent 20 weeks and 16 weeks at their maintenance dose…”. This correctio